Vertex Receives EC’s Approval for the Label Extension of Orkambi to Treat Children with Cystic Fibrosis Aged 1 to <2 Years
July 5, 2023
Vertex’s Orkambi (lumacaftor/ivacaftor) Receives EMA’s CHMP Positive Opinion for Children With Cystic Fibrosis Ages 1 to <2 Years
April 27, 2023
Vertex’s Trikafta Receives the US FDA’s Approval for the Treatment of Children with Cystic Fibrosis Aged 2 Through 5 Years
April 26, 2023
Vertex’s Orkambi (lumacaftor/ivacaftor) Receives Health Canada’s Market Authorization for Children with Cystic Fibrosis Aged 1 to...
April 11, 2023
Vertex Entered into a Non-Exclusive License Agreement with CRISPR Therapeutics to Advance Hypoimmune Cell Therapies for Type 1 Dia...
March 28, 2023
Vertex Receives the US FDA’s IND Clearance of VX-264 for the Treatment of Type 1 Diabetes
March 10, 2023
Back to Home
Incisive News in 3 Shots.
First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2023 PharmaShots - All Rights Reserved.